<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04023903</url>
  </required_header>
  <id_info>
    <org_study_id>RTA 402-009</org_study_id>
    <nct_id>NCT04023903</nct_id>
  </id_info>
  <brief_title>A Clinical Pharmacology Study of Bardoxolone Methyl in Healthy Adults</brief_title>
  <official_title>A Clinical Pharmacology Study of RTA 402 (Investigation of the Effect of Food on the Pharmacokinetics of RTA 402 Capsules in Japanese Healthy Adults and Comparison of the Pharmacokinetics With Those in Caucasian Healthy Adults)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Food effect part:

      To investigate the effect of food on the pharmacokinetics of RTA 402 and evaluate the safety
      of RTA 402 in Japanese healthy male adults, using the capsule formulations.

      Caucasian subject part:

      To investigate the pharmacokinetics of a single dose of RTA 402 administered in the fasted
      state and compare the pharmacokinetics with those observed in Japanese healthy male adults in
      the food effect part
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Actual">June 14, 2019</completion_date>
  <primary_completion_date type="Actual">June 14, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 30, 36, 48, 60, 72, 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 30, 36, 48, 60, 72, 96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 30, 36, 48, 60, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-âˆž</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 30, 36, 48, 60, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 30, 36, 48, 60, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 30, 36, 48, 60, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kel</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 30, 36, 48, 60, 72, 96 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Subject</condition>
  <arm_group>
    <arm_group_label>RTA 402 5mg 3cap at fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RTA 402 5mg 3cap after meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone methyl</intervention_name>
    <description>Bardoxolone methyl 5 mg capsules</description>
    <arm_group_label>RTA 402 5mg 3cap at fasting</arm_group_label>
    <other_name>RTA 402</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone methyl</intervention_name>
    <description>Bardoxolone methyl 5 mg capsules</description>
    <arm_group_label>RTA 402 5mg 3cap after meal</arm_group_label>
    <other_name>RTA 402</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1) Written voluntary informed consent to participate in the study; 2) [Food Effect Part]
        Japanese men 20 to &lt;40 years of age at informed consent; [Caucasian Subject Part] Caucasian
        men 20 to &lt;40 years of age at informed consent; 3) BMI 18.5 kg/m2 to &lt;25.0 kg/m2 at
        screening

        Exclusion Criteria:

          1. Presence of any disease requiring treatment;

          2. History of heart failure (e.g., history of diagnosis of congestive heart failure
             categorized as Class III or IV of the New York Heart Association (NYHA) Functional
             Classification or history of hospitalization due to heart failure);

          3. Alcoholism or drug addiction, or any positive result on drug abuse testing;

          4. History of or current drug allergy;

          5. Any positive result on infectious disease testing. Individuals who are positive for
             active antibodies produced by hepatitis B vaccination and are not infected with
             hepatitis B virus at screening can be enrolled in the study;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Corporation Heishinkai OPHAC Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>532-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bardoxolone Methyl</keyword>
  <keyword>Healthy subject</keyword>
  <keyword>Food effect</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

